Medical Laboratories of Eastern Iowa LC

Medical Laboratories of Eastern Iowa LC was paid $14.45M by Medicaid between Jan 2018 and Dec 2024, across 177 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 14% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Iowa

Rank by total paid#2 of 35

Median peer was paid$42K

This provider vs. median347×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	92,017	$1.62M
2019	89,494	$1.79M
2020	74,091	$1.73M
2021	106,020	$3.91M
2022	114,423	$2.66M
2023	102,236	$1.71M
2024incomplete	60,415	$1.02M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	14%	26,578	25,515	$2.01M
0202U	Oncology (prostate), multianalyte, gene expression profiling	12%	4,625	4,511	$1.79M
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	7.9%	34,672	33,149	$1.14M
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	5.2%	5,732	5,552	$754K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	4.5%	4,823	4,580	$651K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	3.6%	4,053	3,910	$523K
0240U		3.4%	4,120	3,994	$497K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	3.0%	18,600	17,886	$430K
80050	General health panel	2.6%	8,074	7,809	$370K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	2.5%	9,221	8,459	$359K
87507		2.3%	993	960	$326K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	2.1%	9,099	8,655	$302K

165 more codes

87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	2.1%	9,094	$302K
36415	Collection of venous blood by venipuncture	1.9%	74,984	$281K
80061	Lipid panel	1.9%	24,573	$275K
84443	Thyroid stimulating hormone (TSH)	1.9%	20,442	$274K
80053	Comprehensive metabolic panel	1.4%	23,119	$205K
87581		1.2%	4,825	$177K
87486		1.2%	4,827	$177K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	1.2%	6,441	$172K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.2%	26,219	$170K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.1%	6,563	$159K
83036	Hemoglobin; glycosylated (A1C)	<1%	17,986	$139K
87660		<1%	7,298	$135K
87480		<1%	7,300	$135K
87510		<1%	7,302	$135K
80048	Basic metabolic panel (calcium, ionized)	<1%	17,866	$127K
83655		<1%	9,526	$113K
86003		<1%	2,278	$110K
87086	Culture, bacterial; quantitative colony count, urine	<1%	14,952	$106K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	5,056	$105K
84439		<1%	13,606	$103K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	2,062	$92K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	1,622	$75K
86738		<1%	5,790	$75K
82728		<1%	5,558	$63K
85027		<1%	9,816	$57K
86480		<1%	1,025	$53K
86235		<1%	647	$51K
87430		<1%	3,428	$51K
86141		<1%	4,027	$48K
87077		<1%	6,157	$48K
86803		<1%	3,924	$48K
87631		<1%	978	$47K
87186		<1%	5,217	$41K
83970		<1%	1,289	$40K
82607		<1%	3,083	$38K
84153		<1%	2,221	$37K
81001		<1%	12,677	$37K
81025		<1%	4,772	$36K
87506		<1%	168	$34K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	894	$33K
86481		<1%	419	$32K
84403		<1%	1,351	$31K
80074		<1%	749	$29K
86780		<1%	2,338	$27K
82043		<1%	5,367	$26K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	840	$24K
36416		<1%	17,240	$23K
84481		<1%	1,457	$22K
86225		<1%	1,759	$21K
83516		<1%	1,687	$21K
83550		<1%	2,788	$20K
83001		<1%	1,237	$20K
87529		<1%	457	$20K
84702		<1%	1,590	$20K
83540		<1%	3,606	$20K
86038		<1%	1,738	$19K
82746		<1%	1,405	$17K
82784		<1%	1,744	$17K
85610		<1%	5,502	$17K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	188	$16K
81003		<1%	7,717	$16K
82570		<1%	3,647	$15K
83735		<1%	2,849	$15K
85018		<1%	6,483	$15K
86618		<1%	849	$13K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	178	$13K
83690		<1%	2,008	$12K
0353U		<1%	2,361	$12K
80076		<1%	1,774	$12K
87807		<1%	918	$12K
87070		<1%	1,489	$12K
82670		<1%	485	$11K
84703		<1%	1,548	$11K
85652		<1%	4,408	$11K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	173	$10K
82247		<1%	2,189	$10K
84402		<1%	435	$10K
83880		<1%	311	$10K
86364		<1%	938	$9K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	139	$9K
86376		<1%	712	$9K
83002		<1%	555	$9K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	270	$8K
86308		<1%	1,733	$8K
82533		<1%	492	$7K
86592		<1%	1,731	$7K
82947		<1%	2,106	$7K
84146		<1%	401	$7K
84460		<1%	1,616	$7K
87505		<1%	61	$7K
84550		<1%	1,748	$7K
85730		<1%	1,440	$7K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	56	$6K
84450		<1%	1,562	$6K
82150		<1%	1,052	$6K
87205		<1%	1,557	$6K
86431		<1%	1,102	$6K
86140		<1%	1,207	$5K
87340		<1%	571	$5K
82274		<1%	282	$4K
83520		<1%	232	$4K
85379		<1%	476	$4K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	109	$4K
86695		<1%	243	$4K
80069		<1%	544	$4K
82248		<1%	772	$4K
83721		<1%	527	$4K
84156		<1%	1,209	$3K
82465		<1%	1,044	$3K
87641		<1%	114	$3K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	39	$3K
82785		<1%	195	$3K
86696		<1%	153	$3K
86147		<1%	56	$2K
87522	Neg quan hep c or qual rna	<1%	60	$2K
87338		<1%	167	$2K
83921		<1%	94	$2K
86146		<1%	38	$1K
84100		<1%	354	$1K
87046		<1%	56	$1K
85390		<1%	103	$1K
85014		<1%	601	$1K
87210		<1%	215	$1K
86706		<1%	127	$1K
82550		<1%	188	$1K
84480		<1%	73	$971.51
82962		<1%	490	$966.41
85613		<1%	138	$956.85
80164		<1%	90	$943.38
87536		<1%	15	$939.09
88141		<1%	41	$903.96
80177		<1%	83	$893.56
82977		<1%	158	$874.64
82565		<1%	185	$699.38
84165		<1%	71	$592.21
86694		<1%	31	$538.78
87081		<1%	93	$518.70
86334		<1%	31	$482.94
83525		<1%	40	$457.22
86812		<1%	30	$449.28
87045		<1%	56	$433.72
85060		<1%	113	$432.64
84484		<1%	37	$405.52
86359		<1%	14	$398.25
86200		<1%	29	$332.10
87493		<1%	12	$275.44
86360		<1%	14	$270.00
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	30	$236.56
87899		<1%	12	$233.89
82627		<1%	15	$232.32
86800		<1%	12	$190.55
G0472	Hepatitis c antibody screening, for individual at high risk and other covered indication(s)	<1%	53	$157.32
87324		<1%	13	$140.60
81015		<1%	60	$137.68
86255		<1%	14	$127.26
84132		<1%	33	$126.34
85046		<1%	27	$124.43
86705		<1%	12	$113.88
87177		<1%	12	$106.52
99001		<1%	39	$10.44
3046F		0%	168	$0.00
3051F		0%	228	$0.00
0352U		0%	2,257	$0.00
3044F		0%	1,211	$0.00
3052F		0%	123	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTOWNSEND, THEODORE (PRESIDENT/CEO)